Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 10/20 | 0.62 |
| ▸ | CDK1 | P06493 | 2/20 | 0.54 |
| ▸ | DHFR | P00374 | 2/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | CHUK | O15111 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10485673 | 0.85 | APP (0.64) | APPCDK1DHFRNPSR1CHUK | |
| SCHEMBL7152948 | 0.78 | PDE5A (0.54) | APP | |
| SCHEMBL13009791 | 0.77 | APP (1.00) | APPNPSR1 | |
| SCHEMBL3422229 | 0.75 | APP (0.60) | APPCDK1NPSR1EGFRCHUK | |
| SCHEMBL18627615 | 0.75 | LDHA (0.54) | APPCDK1DHFREGFRSMN1; SMN2 | |
| SCHEMBL3301514 | 0.74 | NPSR1 (0.74) | APPDHFRNPSR1SMN1; SMN2 | |
| SCHEMBL6727019 | 0.74 | NPSR1 (0.74) | APPDHFRNPSR1SMN1; SMN2 | |
| SCHEMBL6128301 | 0.73 | APP (0.57) | APPCDK1NPSR1EGFR | |
| Hydrochloric Acid SCHEMBL9247173 | 0.73 | NPSR1 (0.72) | APPDHFRNPSR1SMN1; SMN2 | |
| SCHEMBL7022867 | 0.72 | SMN1; SMN2 (0.68) | APPDHFRNPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | KOSOGOF CHRISTI (US) | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171131-A1 | Diaminopyrimidine derivatives as growth hormone secrectgogue receptor (GHS-R) antagonists | GHSR, GIPR, GPR119 | APP 2440/4885CDK1 1470/4885DHFR 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.